Arcturus Completes ARCT810 Phase 2 Enrollment and Dosing
Arcturus Therapeutics said enrollment is complete and all participants have finished study-drug dosing in its ARCT810 Phase 2 trial for OTC deficiency. The company expects to report clinical data in Q3 2026.